<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770886</url>
  </required_header>
  <id_info>
    <org_study_id>UE2343</org_study_id>
    <nct_id>NCT01770886</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Oral UE2343 in Healthy Subjects</brief_title>
  <acronym>UE2343</acronym>
  <official_title>A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised, double-blind, placebo-controlled, phase I study in healthy subjects. Safety,&#xD;
      pharmacokinetic and pharmacodynamic data will be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of UE2343 in healthy male/female subjects</measure>
    <time_frame>At each dose</time_frame>
    <description>Days 1-2 at each dose:&#xD;
12 lead ECG&#xD;
Vital signs&#xD;
Symptom led clinical assessment (day 1 only)&#xD;
Routine laboratory assessments&#xD;
Days 3-6 at each dose:&#xD;
12 lead ECG&#xD;
Vital signs&#xD;
Routine laboratory assessments&#xD;
Day 10 at each dose:&#xD;
12 lead ECG&#xD;
Vital signs&#xD;
Routine laboratory assessments&#xD;
Physical examination&#xD;
Pregnancy test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of UE2343 and pharmacodynamic exposure</measure>
    <time_frame>At each dose</time_frame>
    <description>Days 1-2 at each dose:&#xD;
Blood and urine samples for measurement of UE2343&#xD;
Blood samples for adrenal androgens&#xD;
Blood samples for ACTH and cortisol&#xD;
Urine samples for urinary free steroids&#xD;
Days 3-6 at each dose:&#xD;
Blood and urine samples for measurement of UE2343&#xD;
Blood samples for adrenal androgens&#xD;
Blood samples for ACTH and cortisol&#xD;
Urine samples for urinary free steroids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>UE2343</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UE2343</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>UE2343</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects between 18 and 65 years of age (inclusive).&#xD;
&#xD;
          -  Female subject is postmenopausal or surgically sterilized or had a hysterectomy.&#xD;
&#xD;
          -  Female subject with negative pregnancy test.&#xD;
&#xD;
          -  Male subjects willing to use an effective method of contraception, if applicable&#xD;
             (unless anatomically sterile or where abstaining from sexual intercourse is in line&#xD;
             with the preferred and usual lifestyle of the subject) from Day 1 until 3 months&#xD;
             afterwards.&#xD;
&#xD;
          -  Subject with a Body Mass Index (BMI) of 18-30 kg/m2. Body Mass Index = Body weight&#xD;
             (kg) / [Height (m)]2.&#xD;
&#xD;
          -  Subject with no clinically significant abnormal serum biochemistry, haematology and&#xD;
             urine examination values or results suggesting an infectious or other systemic&#xD;
             disorder. The parameters to be measured will include those shown in Appendix 2. The&#xD;
             Simbec normal ranges are shown in Appendix 3.&#xD;
&#xD;
          -  Subject with a negative urinary drugs of abuse screen (Appendix 2) (N.B. a positive&#xD;
             alcohol result may be repeated at the discretion of the Investigator).&#xD;
&#xD;
          -  Subject with negative HIV and Hepatitis B and C results.&#xD;
&#xD;
          -  Subject with no clinically significant abnormalities in 12-lead electrocardiogram&#xD;
             (ECG).&#xD;
&#xD;
          -  no clinically significant abnormalities in vital signs.&#xD;
&#xD;
          -  willing and able to comply with the requirements of the protocol.&#xD;
&#xD;
          -  satisfy a medical examiner about fitness to participate in the study.&#xD;
&#xD;
          -  provide written informed consent to participate in the study.&#xD;
&#xD;
          -  Smokers are eligible to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relevant abnormality in medical history or on examination, including history of&#xD;
             dementia, or other psychiatric, neurological, immunological, respiratory or&#xD;
             cardiovascular disorder. Particularly exclude subjects with signs of peripheral&#xD;
             neuropathy. Abnormal laboratory findings suggesting the presence of a systematic&#xD;
             disorder.&#xD;
&#xD;
          -  Participation in a clinical study of an unlicensed drug in the previous 4 months, or a&#xD;
             marketed drug study within the previous 3 months. (N.B. washout period between trials&#xD;
             defined as the period of time elapsed between the last dose of the previous study and&#xD;
             the first dose of the next study).&#xD;
&#xD;
          -  Known allergies, including allergy to chemicals like and excipients associated with&#xD;
             UE2343.&#xD;
&#xD;
          -  Recent or clinically significant history of drug or alcohol abuse.&#xD;
&#xD;
          -  Blood donation greater than 500 ml in the previous 3 months.&#xD;
&#xD;
          -  Inability to communicate well with the Investigator (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function).&#xD;
&#xD;
          -  Receipt of regular prescribed medication within 7 days of the first study day and / or&#xD;
             receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7&#xD;
             days of the first study day. Subjects taking long lasting drugs more than 7 days&#xD;
             before the study may be excluded at the physician's discretion. Inclusion of subjects&#xD;
             who have taken over the counter drugs during this period will be reviewed on a&#xD;
             case-by-case basis in relation to the safety aspects and objectives of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian R Walker, BSc MBChB MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>July 16, 2013</last_update_submitted>
  <last_update_submitted_qc>July 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

